Jasper Therapeutics financials
$0.6254−0.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$9.2M | -$11.0M | -$15.8M | -$19.2M | -$27.1M | -$21.8M | -$25.3M | -$19.9M | -$16.0M | -$15.1M | -$17.7M | -$19.4M |
| Net income | -$2.8M | -$1.2M | -$9.1M | -$18.7M | -$26.7M | -$21.2M | -$24.3M | -$18.6M | -$14.6M | -$13.7M | -$16.6M | -$17.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.10 | $-0.04 | $-0.31 | $-1.13 | $-1.74 | $-1.41 | $-1.62 | $-1.24 | $-0.97 | $-1.03 | $-1.50 | $-1.60 |
| EBITDA | -$9.2M | -$10.9M | -$15.5M | -$18.9M | -$26.8M | -$21.5M | -$25.0M | -$19.3M | -$15.7M | -$14.8M | -$17.4M | -$19.1M |
| Operating cash flow | -$6.9M | -$14.5M | -$21.9M | -$17.0M | -$15.5M | -$22.8M | -$21.1M | -$14.1M | -$11.7M | -$15.7M | -$16.5M | -$12.0M |
| Free cash flow | -$6.9M | -$14.5M | -$21.9M | -$17.0M | -$15.5M | -$22.8M | -$21.2M | -$14.3M | -$11.8M | -$15.8M | -$16.7M | -$12.0M |
| Diluted shares | 28.7M | 28.7M | 29.7M | 16.6M | 15.3M | 15.0M | 15.0M | 15.0M | 15.0M | 13.3M | 11.1M | 11.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.3M | $14.1M | $28.7M | $50.9M | $39.5M | $48.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $11.8M | $21.2M | $35.8M | $57.5M | $46.5M | $57.6M |
| Total liabilities | $10.4M | $17.8M | $31.6M | $45.9M | $23.0M | $15.4M |
| Shareholders' equity | $1.4M | $3.4M | $4.2M | $11.6M | $23.5M | $42.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology